A personalised cancer vaccine built on the same mRNA technology that powered Covid-19 shots has shown striking results in a landmark trial, stopping melanoma from returning in patients who had been operated on for high-risk skin cancer.
Pharmaceutical giants Moderna and Merck announced this week the preliminary results of their Phase 3 trial — the largest and most advanced stage of clinical testing — involving 1,000 participants with high-risk melanoma. The trial assessed the vaccine in combination with Keytruda (pembrolizumab), an immunotherapy drug already widely used in cancer treatment.
The vaccine, known as mRNA-4157, works by sequencing the DNA of each patient's tumour to identify unique genetic "fingerprints" called neoantigens — mutations found only in that person's cancer. Scientists then construct a personalised mRNA vaccine that trains the immune system to recognise and attack those specific cancer cells while leaving healthy tissue alone.
It is, in effect, a custom-made weapon against cancer — one tailored to the individual at the molecular level.
"A Pivotal Moment"
Moderna CEO Stéphane Bancel called the preliminary findings "a pivotal moment" for cancer research. The company reported that the vaccine extended cancer-free periods for trial participants, though precise durations were not disclosed ahead of the full data release.
Independent experts were cautiously enthusiastic. Dr Lennard Lee, Associate Professor at the University of Oxford, called the findings "a landmark moment for cancer vaccines." Professor Peter Johnson, National Clinical Director for Cancer at NHS England, told the BBC: "It feels like it's a very important advance."
The full results have not yet been peer-reviewed or published in a scientific journal, and researchers cautioned that further scrutiny is needed before drawing firm conclusions. But even preliminary data from Phase 3 trials carry weight — they represent the final hurdle before regulators can consider approval.
How mRNA Changed Everything
The mRNA platform, developed and refined during the Covid-19 pandemic, proved it could move at unprecedented speed while remaining highly flexible. Where traditional vaccines use weakened virus particles or protein fragments, mRNA vaccines deliver genetic instructions that teach cells to produce a target protein — in this case, the specific proteins found on a patient's cancer cells.
For cancer, the advantage is personalisation. No two tumours are identical. Conventional cancer drugs often target common mutations shared across many patients, meaning they work well for some and poorly for others. mRNA-4157 sidesteps this by being rebuilt from scratch for every individual.
The personalised approach has long been considered a holy grail of oncology — theoretically capable of dramatically improving outcomes where existing treatments fall short. Melanoma, while more treatable than many cancers when caught early, remains deadly when it spreads, making better post-surgical options urgently needed.
What Comes Next
Moderna and Merck are expected to share full Phase 3 data in the coming months, allowing independent review by the scientific community and regulators. If the complete results hold up, the companies could apply for regulatory approval — a process that typically takes one to two years.
The trial focuses on high-risk melanoma patients after surgery, a group at significant risk of recurrence. If approved, the vaccine would represent the first personalised mRNA cancer therapeutic to reach the market — a milestone that could open the door to similar vaccines targeting lung, colorectal, and pancreatic cancer.
Scientists involved in the project noted that mRNA-4157 is already being studied for other tumour types, suggesting that today's melanoma results may be just the beginning of a broader transformation in how cancer is treated.
For patients who previously faced long odds after high-risk surgery, the technology — if confirmed — offers something rare: a genuine reason for hope, built one patient at a time.
